Index
S&P 500
P/E
24.63
EPS (ttm)
3.59
Insider Own
0.68%
Shs Outstand
1.74B
Perf Week
-1.38%
Market Cap
153.99B
Forward P/E
14.61
EPS next Y
6.05
Insider Trans
0.33%
Shs Float
1.73B
Perf Month
-0.46%
Enterprise Value
181.39B
PEG
1.55
EPS next Q
1.28
Inst Own
81.45%
Perf Quarter
-17.52%
Income
6.28B
P/S
3.41
EPS this Y
6.29%
Inst Trans
0.24%
Perf Half Y
-30.31%
Sales
45.13B
P/B
2.96
EPS next Y
10.56%
ROA
6.54%
Perf YTD
-29.44%
Book/sh
29.89
P/C
21.11
EPS next 5Y
9.42%
ROE
12.45%
52W High
139.06 -36.42%
Perf Year
-33.23%
Cash/sh
4.19
P/FCF
20.87
EPS past 3/5Y
-1.70% 8.23%
ROIC
7.68%
52W Low
81.97 7.86%
Perf 3Y
-16.75%
EV/EBITDA
16.22
Sales past 3/5Y
0.51% 5.08%
Gross Margin
52.84%
Volatility
2.71% 2.17%
Perf 5Y
-19.87%
EV/Sales
4.02
EPS Y/Y TTM
-53.44%
Oper. Margin
17.77%
ATR (14)
2.17
Perf 10Y
136.45%
Quick Ratio
1.01
Sales Y/Y TTM
6.59%
Profit Margin
13.91%
RSI (14)
47.55
Current Ratio
1.39
EPS Q/Q
-17.14%
SMA20
0.01%
Beta
0.61
Debt/Eq
0.65
Sales Q/Q
7.78%
SMA50
-1.91%
Rel Volume
3.16
Prev Close
88.50
Employees
115000
LT Debt/Eq
0.57
SMA200
-22.20%
Avg Volume
13.17M
Price
88.41
IPO
Mar 01, 1937
Option/Short
Yes / Yes
Trades
Volume
41,627,170
Change
-0.10%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-26 Downgrade
Daiwa Securities
Outperform → Neutral
$92
Oct-10-25 Initiated
The Benchmark Company
Buy
$145
Jul-18-25 Upgrade
Jefferies
Hold → Buy
$145
Jun-16-25 Initiated
Leerink Partners
Market Perform
$143
Oct-08-24 Initiated
Oppenheimer
Outperform
$130
Sep-19-24 Initiated
Piper Sandler
Overweight
$131
Jul-30-24 Downgrade
Edward Jones
Buy → Hold
May-30-24 Initiated
Goldman
Buy
$121
Jul-21-23 Upgrade
Wolfe Research
Underperform → Peer Perform
May-30-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$112
Apr-20-23 Reiterated
Wolfe Research
Underperform
$107 → $103
Apr-20-23 Reiterated
UBS
Buy
$117 → $130
Apr-20-23 Reiterated
Raymond James
Outperform
$116 → $123
Apr-20-23 Reiterated
JP Morgan
Overweight
$118 → $122
Apr-20-23 Reiterated
Bernstein
Outperform
$132 → $133
Apr-20-23 Reiterated
Barclays
Overweight
$125 → $127
Mar-29-23 Initiated
UBS
Buy
$117
Oct-26-22 Initiated
Mizuho
Neutral
$105
Oct-18-22 Initiated
Barclays
Overweight
$118
Oct-12-22 Initiated
Jefferies
Hold
$110
Show Previous Ratings
Today 02:14PM
12:03PM
Jun-12-26 02:29PM
Jun-11-26 12:01PM
Jun-08-26 09:00AM
09:00AM
Loading…
Jun-06-26 09:00AM
Jun-04-26 03:39PM
Jun-03-26 07:53AM
May-29-26 08:47AM
May-28-26 07:20AM
May-27-26 03:02PM
09:00AM
07:01AM
May-26-26 09:00AM
May-22-26 10:04PM
05:30AM
Loading…
May-20-26 05:30AM
(The Wall Street Journal)
May-16-26 10:10AM
May-15-26 04:55AM
01:00AM
May-13-26 07:08AM
May-12-26 01:00PM
May-09-26 07:46AM
May-07-26 03:50PM
May-04-26 05:53PM
Apr-29-26 06:22PM
Apr-27-26 01:14PM
Apr-25-26 12:30PM
Apr-22-26 11:28AM
Apr-21-26 11:59AM
Apr-20-26 11:18AM
04:13PM
Loading…
Apr-17-26 04:13PM
03:30PM
03:02AM
Apr-16-26 03:14PM
02:53PM
(The Wall Street Journal)
12:46PM
11:22AM
(The Wall Street Journal)
10:48AM
09:03AM
(Investor's Business Daily)
08:09AM
08:05AM
07:56AM
07:30AM
05:00AM
Apr-13-26 07:11AM
Apr-10-26 08:00PM
06:58PM
03:09PM
12:12AM
Apr-09-26 09:00AM
Apr-08-26 09:31AM
Apr-01-26 06:47AM
Mar-31-26 04:42PM
12:58PM
12:03PM
11:59AM
07:32AM
06:00AM
06:00AM
Mar-30-26 09:00AM
Mar-27-26 06:16AM
Mar-26-26 06:55PM
06:06PM
03:00PM
09:00AM
Mar-24-26 08:00AM
06:05AM
(Milwaukee Journal Sentinel)
Mar-23-26 09:37AM
08:50AM
Mar-20-26 09:00AM
06:57AM
Mar-16-26 07:30PM
Mar-12-26 03:00AM
Mar-11-26 03:26PM
11:00AM
06:00AM
05:27AM
Mar-10-26 10:58AM
09:45AM
Mar-09-26 05:50PM
Mar-06-26 11:30AM
09:52AM
Mar-05-26 03:00AM
Mar-04-26 09:00AM
Mar-03-26 09:10AM
Mar-02-26 05:50PM
01:32AM
Mar-01-26 11:05PM
Feb-26-26 05:00PM
11:21AM
08:14AM
03:36AM
Feb-25-26 09:11AM
Feb-24-26 11:33AM
Feb-23-26 05:50PM
03:41PM
12:07PM
09:30AM
Feb-20-26 04:05PM
03:13PM
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
CFO & Executive VP of Finance Mr. Philip P. Boudreau
Executive VP and Group President of Established Pharmaceuticals & Nutritional Products Mr. Daniel Gesua Sive Salvadori
Executive Vice President of Diabetes Care Mr. Christopher J. Scoggins
Executive VP & Group President of Medical Devices Ms. Lisa D. Earnhardt
Senior VP of Business & Technology Services and Chief Information Officer Ms. Sabina Ewing
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Stratton John G Director May 07 '26 Buy 86.82 2,000 173,640 23,319 Jun 18 05:08 PM Robert J. Alpern Retired Director May 15 '26 Proposed Sale 85.25 7,587 646,791 May 15 04:15 PM STARKS DANIEL J Director Apr 27 '26 Buy 92.65 10,000 926,537 6,751,103 Apr 28 07:37 PM Robert J. Alpern Retired Director Apr 27 '26 Proposed Sale 92.55 29,211 2,703,457 Apr 27 06:34 PM Boudreau Philip P EVP AND CFO Apr 23 '26 Buy 91.50 2,200 201,300 2,200 Apr 27 05:34 PM Shroff Eric Senior Vice President Mar 02 '26 Sale 115.58 709 81,946 39,164 Mar 03 08:20 PM Salvadori Daniel Gesua Sive EVP AND GROUP PRESIDENT Mar 02 '26 Sale 115.58 885 102,288 146,377 Mar 03 08:10 PM Morrone Louis H. EXECUTIVE VICE PRESIDENT Mar 02 '26 Sale 115.58 1,144 132,224 76,843 Mar 03 08:06 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Mar 02 '26 Sale 115.58 613 70,851 104,291 Mar 03 08:00 PM MCCOY JOHN A. JR. VICE PRESIDENT AND CONTROLLER Mar 02 '26 Sale 115.58 585 67,614 24,628 Mar 03 07:55 PM Cushman Elizabeth C. EVP, GC AND SECRETARY Mar 02 '26 Sale 115.58 263 30,398 38,573 Mar 03 07:39 PM Eric Shroff Officer Mar 02 '26 Proposed Sale 115.58 709 81,946 Mar 02 08:36 PM Daniel Gesua Sive Salvadori Officer Mar 02 '26 Proposed Sale 115.58 885 102,288 Mar 02 08:23 PM Louis H. Morrone Officer Mar 02 '26 Proposed Sale 115.58 1,144 132,223 Mar 02 08:16 PM Mary K. Moreland Officer Mar 02 '26 Proposed Sale 115.58 613 70,850 Mar 02 08:05 PM John A. McCoy, Jr. Officer Mar 02 '26 Proposed Sale 115.58 585 67,614 Mar 02 07:59 PM Elizabeth C. Cushman Officer Mar 02 '26 Proposed Sale 115.58 263 30,397 Mar 02 07:53 PM STARKS DANIEL J Director Feb 04 '26 Buy 108.73 10,000 1,087,331 6,738,817 Feb 06 08:04 AM Ford Robert B CHAIRMAN AND CEO Jan 23 '26 Buy 107.13 18,800 2,013,967 216,203 Jan 26 08:02 AM Shroff Eric Senior Vice President Nov 25 '25 Sale 128.02 1,586 203,043 30,384 Nov 25 04:17 PM Eric Shroff Officer Nov 25 '25 Proposed Sale 128.02 1,586 203,042 Nov 25 04:08 PM Boudreau Philip P EVP AND CFO Aug 08 '25 Sale 134.55 5,550 746,758 51,003 Aug 11 05:53 PM Boudreau Philip P Officer Aug 08 '25 Proposed Sale 134.55 5,550 746,758 Aug 08 06:30 PM